Vishwa Jeet Amatya
Overview
Explore the profile of Vishwa Jeet Amatya including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
82
Citations
723
Followers
0
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Onishi S, Yamasaki F, Amatya V, Yonezawa U, Taguchi A, Ozono I, et al.
J Neurooncol
. 2024 Dec;
172(1):185-194.
PMID: 39636550
Background: H3 histone 27 lysine (H3K27) trimethylation (H3K27me3), which is catalyzed by enhancer of zeste homolog 2 (EZH2), regulates gene expression through epigenetic mechanisms. H3K27me3 is used as a diagnostic...
2.
Onishi S, Yamasaki F, Akiyama Y, Kawahara D, Amatya V, Yonezawa U, et al.
J Neurooncol
. 2024 Aug;
170(2):429-436.
PMID: 39133381
Introduction: The T2-FLAIR mismatch sign is a characteristic imaging biomarker for astrocytoma, isocitrate dehydrogenase (IDH)-mutant. However, investigators have provided varying interpretations of the positivity/negativity of this sign given for individual...
3.
Onishi S, Kojima M, Yamasaki F, Amatya V, Yonezawa U, Taguchi A, et al.
Neurosurg Rev
. 2024 Aug;
47(1):412.
PMID: 39117984
Introduction: The WHO classification of central nervous system tumors (5th edition) classified astrocytoma, IDH-mutant accompanied with CDKN2A/B homozygous deletion as WHO grade 4. Loss of immunohistochemical (IHC) staining for methylthioadenosine...
4.
Ozono I, Onishi S, Yonezawa U, Taguchi A, Khairunnisa N, Amatya V, et al.
J Neurooncol
. 2024 Jul;
169(3):571-579.
PMID: 38995493
Purpose: The T2-FLAIR mismatch sign is a highly specific diagnostic imaging biomarker for astrocytoma, IDH-mutant. However, a definitive prognostic imaging biomarker has yet to be identified. This study investigated imaging...
5.
Onishi S, Yamasaki F, Kinoshita Y, Amatya V, Yonezawa U, Taguchi A, et al.
J Neurosurg
. 2024 Jun;
141(6):1614-1622.
PMID: 38848603
Objective: Radiation therapy (RT) improves the outcome of patients with cancer but introduces the risk of radiation-induced neoplasms in cancer survivors. The most common radiation-induced brain tumors (RIBTs) are gliomas...
6.
Izaki Y, Amatya V, Kambara T, Kushitani K, Miyata Y, Okada M, et al.
Cancers (Basel)
. 2023 Dec;
15(23).
PMID: 38067335
Small cell lung cancer (SCLC) and large cell neuroendocrine carcinoma (LCNEC) have recently been grouped as lung neuroendocrine carcinomas (NECs). Because these lung NECs are clinically malignant and their treatment...
7.
Taguchi A, Kinoshita Y, Amatya V, Onishi S, Go Y, Tominaga A, et al.
Neurosurg Rev
. 2023 Nov;
46(1):317.
PMID: 38030890
Purpose: To clarify the invasiveness to surrounding structures and recurrence rate of each subtype of nonfunctioning pituitary neuroendocrine tumor (Pit-NETs) according to the WHO 2022 classification. Methods: This retrospective study...
8.
Endo I, Amatya V, Kushitani K, Nakagiri T, Aoe K, Takeshima Y
Anticancer Res
. 2023 Nov;
43(12):5367-5376.
PMID: 38030172
Background/aim: Long non-coding RNAs (lncRNAs) establish gene regulatory networks in different human cancers and are involved in tumorigenesis. lncRNA LINC00152 is over-expressed in several malignant tumors and involved in tumorigenesis;...
9.
Onishi S, Yamasaki F, Amatya V, Takayasu T, Yonezawa U, Taguchi A, et al.
J Neurooncol
. 2023 Oct;
165(1):171-179.
PMID: 37831389
Background: The treatment response of primary central nervous system lymphomas (PCNSLs) is mainly evaluated using postcontrast T1-weighted imaging (T1WI). Because poorly enhanced lesions may contain residual tumors, the combination of...
10.
Endo I, Amatya V, Kushitani K, Kambara T, Nakagiri T, Aoe K, et al.
Anticancer Res
. 2023 Aug;
43(9):3961-3968.
PMID: 37648326
Background/aim: Forkhead box M1 (FOXM1) is a transcription factor closely associated with various human malignancies and is considered an attractive target for cancer therapy. Mesothelioma is a malignancy primarily due...